{"id":193834,"name":"ALVOGEN","slug":"alvogen","state":"NJ","description":"Pharmaceutical company developing and manufacturing generic, brand and biosimilar products","totalSpending":1155000,"filings":26,"yearlySpending":[{"year":2018,"income":75000},{"year":2019,"income":135000},{"year":2020,"income":180000},{"year":2021,"income":180000},{"year":2022,"income":270000},{"year":2024,"income":180000},{"year":2025,"income":135000}],"firms":["EAST END GROUP, LLC"],"lobbyists":["MICHAEL WOODY","ANDREW HAWKINS","KELLY CHILDRESS LANGE"],"issues":["HCR","TAR","MAN"],"sampleDescriptions":["Issues related to development and procurement of influenza antivirals. The re-authorization of the Pandemic and All-Hazards Preparedness Act.","Issues related to development and procurement of influenza antivirals. The re-authorization of the Pandemic and All-Hazards Preparedness Act","Funding for pandemic influenza antivirals in the LHHS Appropriations bill. Regulatory issues related to development and procurement of pandemic influenza antivirals.","Funding for pandemic influenza antivirals in the LHHS Appropriations bill. Regulatory and legislative issues related to development and procurement of pandemic influenza antivirals.","Funding for pandemic influenza antivirals in the LHHS Appropriations bill. Regulatory and legislative issues related to development and procurement of pandemic influenza antivirals, and the reauthorization of the Pandemic and All-Hazards Preparedness Act.","Section 232 investigation into pharmaceuticals and unfair trade practices.","Buy America legislation, 232 tariff investigation, regulatory incentives for domestic manufacturing.","Funding for pandemic influenza antivirals in the LHHS Appropriations bill. Regulatory and legislative issues related to development and procurement of pandemic influenza antivirals. Issues related to domestic manufacturing and on-shoring pharmaceuticals."],"years":[2018,2019,2020,2021,2022,2024,2025]}